San Diego-based mostly Viking Therapeutics marked alone as a significant competitor within the weight loss drug market in February after revealing promising info from the mid-stage trial of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when offered for a weekly injection and in March the company unve